Company news

Actinogen Medical Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Updated Xanamem Clinical Development Program

July 29, 2018

June 2018 Quarterly Report

July 25, 2018

Placement under Share Purchase Plan Shortfall

July 18, 2018

New Study Sites Added to Accelarate Patient Recruitment

July 5, 2018

Share Purchase Plan

June 6, 2018

$15m Placement Completed-Including US Cornerstone Investor

May 23, 2018

XanADu Interim Analysis-Continuation Without Change

May 22, 2018

March 2018 Quarterly Report

April 26, 2018

Mid-Way Point Reached in Landmark Alzheimers Trial - XanADu

March 20, 2018

Strong Recruitment Progress in Alzheimers Trial

February 11, 2018

New Data Supports Cortisol Hypothesis

February 5, 2018

December 2017 Quarterly Report

January 31, 2018

Prospectus

December 1, 2017

Early Efficacy & Safety Data Planned for XanADu Trial

November 28, 2017

Placement Fully Funds Completion of XanADu Alzheimers Trial

November 28, 2017

R&D Rebate Received Totalling $1.22 Million

November 14, 2017

Quarterly Update & Appendix 4C

October 30, 2017

Final Major Market Patent Granted for Xanamem

October 10, 2017

First Patient Completes Landmark Alzheimers Disease Trial

September 6, 2017

First UK patient treated in ground-breaking clinical trial

August 15, 2017

June Quarterly Update

July 26, 2017

First US Patients Treated in Landmark Alzheimers Trial

June 21, 2017

First UK Site Goes Live in Global Alzheimers Clinical Trial

May 31, 2017

First Patient Treated in Landmark Alzheimers Clinical Trial

May 15, 2017

March Quarterly Update

April 25, 2017

TGA Regulatory Approval for Alzheimers Phase II Trial

March 7, 2017

Actinogen Medical Financial Results

February 27, 2017

UK Regulatory Approval for Alzheimers Clinical Trial-XanADu

February 9, 2017

Xanamem Research Published in Prestigious Medical Journal

February 8, 2017

Appendix 4C - quarterly

January 22, 2017

FDA Approval to Commence Alzheimers Disease Clinical Trial

January 2, 2017

Significant Advance in Development of Alzheimers Drug

December 18, 2016

FDA Feedback on Xanamem Alzheimers Trail

September 29, 2016

R&D Tax Rebate

September 4, 2016

New Patents Allowed for B-HSD1 Inhibitor

August 2, 2016

Further results in bio-ethanol test program

August 2, 2016

Announcement of non-renounceable rights issue

August 2, 2016

Appendix 4C & Commentary

August 2, 2016

Landmark Research on Excess Cortisol & Alzheimers Disease

July 27, 2016

US Patent Granted-Further Extends Xanamem Protection

July 19, 2016

US FDA Feedback Enhances Alzheimers Study

June 7, 2016

Launch of XanADu Phase II Clinical Trial

March 21, 2016

Appendix 4D & Half Year Report

February 19, 2016

R&D Rebate

February 11, 2016

Update on the Biofuel Research Program

February 10, 2016

Trials recommence on antibiotic project

February 10, 2016

Suspension of ACWN and ACWO 1/08/13

February 10, 2016

Supplementary prospectus - withdrawal of offer

February 10, 2016

Supplementary prospectus and amended timetable

February 10, 2016

Successful Completion of 1st Stage of Alzheimers Drug Trial

February 10, 2016

← Newer news releases · Older news releases →

Decks

The 5 newest of 88 decks. Every deck is listed under its year.